| Literature DB >> 26805065 |
Takeo Hara1, Yoshiyuki Fujiwara, Keijiro Sugimura, Takeshi Omori, Masaaki Motoori, Norikatsu Miyoshi, Hirofumi Akita, Kunihito Gotoh, Hidenori Takahashi, Shogo Kobayashi, Shingo Noura, Masayuki Ohue, Masato Sakon, Masahiko Yano.
Abstract
Peritoneal dissemination (PD) is the most common type of metastasis in advanced gastric cancer. The standard treatment of gastric cancer patients with PD is combination therapy with S-1 and cisplatin (SP therapy). Here, we describe the results of SP therapy for gastric cancer with PD. Sixteen gastric cancer patients with PD were treated with SP therapy as first-line chemotherapy. Second-look staging laparoscopy was performed for 10 patients who showed a good response to SP therapy. Gastrectomy was performed for 5 patients with P0CY0 and 1 case with P0CY1. The median survival time of all 16 patients was 571 days (19 months). The patients, who had surgery, had a significantly better survival time than the others (25 months vs 12.7 months). In conclusion, SP therapy is effective for gastric cancer with PD, and surgery for cases showing a good response to chemotherapy might improve the prognosis of patients with PD.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26805065
Source DB: PubMed Journal: Gan To Kagaku Ryoho ISSN： 0385-0684